By: IPP Bureau
Last updated : November 11, 2021 10:41 am
The Board of Directors of Alembic Pharmaceuticals have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021.
For the quarter ended September 30, 2021(Q2 FY2022), Alembic Pharmaceuticals total income was Rs 1294.52 crore, against Rs 1460.32 crore in the corresponding quarter of the previous year (YoY) and Rs 1327.91 crore in the previous quarter (QoQ).
For the quarter ended September 30, 2021(Q2 FY2022), the company's net profit was Rs 169.29 crore, against Rs 333.37 crore in the corresponding quarter of the previous year (YoY) and Rs 164.52 crore in the previous quarter (QoQ).
For the 6 months ended September 30, 2021(Half Year Ended FY 2022), the company's total income was Rs 2622.43 crore, against Rs 2801.95 crore in the previous year (YoY) (Half Year Ended FY 2021).
The net profit was at Rs 333.81 crore for the 6 months ended September 30, 2021 (Half Year Ended FY 2022), compared to Rs 634.83 crore in the previous year (YoY) (Half Year Ended FY 2021).